“Cognizant has imposed restrictive obligations with no legitimate purpose,” Infosys stated. “These practices deprive customers of competition, resulting in higher prices and limited innovation in the U.S. healthcare system.”
Allegations of Monopolistic Behavior
Infosys’s counterclaims, filed Thursday, accuse Cognizant of leveraging its market dominance and contractual provisions, such as “most-favored vendor” clauses and exclusive agreements, to exclude competitors. Infosys argues that Cognizant’s actions violated Texas antitrust laws and restrained trade by:
- Limiting third-party participation in product training programs.
- Imposing one-sided non-solicitation agreements.
- Restricting the scope of work that competitors could perform for payors.
- Preventing the development of software products that could interface with Cognizant’s systems.
Infosys claims these practices forced healthcare payors covering 65% of insured Americans to rely on costly, outdated systems, causing significant harm to competition and driving up expenses.
Infosys Accuses Cognizant of Sabotaging Innovation
Infosys further alleges that Cognizant recruited high-ranking Infosys executives, including former Infosys President Ravi Kumar S., to sabotage the development of the Infosys Helix platform. Kumar, who joined Cognizant as CEO in October 2022, allegedly delayed Helix’s progress during his tenure at Infosys, setting the project back by 18 months.
